UK markets closed
  • FTSE 100

    7,134.06
    +45.88 (+0.65%)
     
  • FTSE 250

    22,734.13
    +125.37 (+0.55%)
     
  • AIM

    1,249.65
    +3.03 (+0.24%)
     
  • GBP/EUR

    1.1648
    +0.0009 (+0.07%)
     
  • GBP/USD

    1.4117
    -0.0060 (-0.42%)
     
  • BTC-GBP

    25,374.73
    -566.34 (-2.18%)
     
  • CMC Crypto 200

    924.19
    -17.62 (-1.87%)
     
  • S&P 500

    4,247.44
    +8.26 (+0.19%)
     
  • DOW

    34,479.60
    +13.36 (+0.04%)
     
  • CRUDE OIL

    70.78
    +0.49 (+0.70%)
     
  • GOLD FUTURES

    1,879.50
    -16.90 (-0.89%)
     
  • NIKKEI 225

    28,948.73
    -9.83 (-0.03%)
     
  • HANG SENG

    28,842.13
    +103.25 (+0.36%)
     
  • DAX

    15,693.27
    +122.05 (+0.78%)
     
  • CAC 40

    6,600.66
    +54.17 (+0.83%)
     

United States Hepatitis Vaccines Market Report 2021: Key Marketed Vaccines are Havrix/Twinrix/Engerix-B, Vaqta, Recombivax HB & Heplisav-B - Forecast to 2027

·3-min read

Dublin, May 31, 2021 (GLOBE NEWSWIRE) -- The "U.S. Hepatitis Vaccines Market - Growth, Demand, Trends, Opportunity, Forecasts (2021 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The United States hepatitis vaccines market is projected to boost over the forecast period of 2021 to 2027.

This new market report provides a comprehensive analysis of the fast-evolving, high-growth U.S hepatitis vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the U.S. hepatitis vaccines market. The report provides historical market data for 2015 - 2020, and forecasts from 2021 till 2027.

The report additionally provides a detailed evaluation of the leading 6 key marketed hepatitis vaccines market assessments, data from 2015 to 2020, and forecasts to 2027. Additionally, this up-to-date report describes the latest features reimbursement pattern and offers a clear view of the regulatory framework of the United States hepatitis vaccines market.

An all-inclusive examination has been done on the pricing trends and analysis of the hepatitis vaccines in the United States. The report also offers detailed information about the recruiting clinical trials statement by phase, trial status, study sponsor name, and study phase. The report also delivers an in-depth analysis of evolving market trends, drivers, and restraining forces that influence the growth of the market.

The report concludes with the profiles of the key players in the U.S. hepatitis vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, and recent development.

Other emerging players are making novel era-based vaccines that are in all possible to have an effect on the market share during the forecast duration. The emerging players are evaluated on various parameters such as business overview, promising vaccines in the clinical development with the current stage of clinical evaluation, vaccines target, platform technology, and recent developments.

Key Questions Answered in this Report:

  • What is the current scenario of the U.S. hepatitis vaccines market?

  • What is the total market size and forecast (until 2027) for the U.S. hepatitis vaccines market?

  • What are the key marketed hepatitis vaccines available in the United States?

  • What are the major drivers of the United States hepatitis vaccines market?

  • What are the major inhibitors of the United States hepatitis vaccines market?

  • What is the reimbursement pattern in the United States hepatitis vaccines market?

  • What is the regulatory framework in the United States hepatitis vaccines market?

  • What are the upcoming hepatitis vaccines that will have a significant impact on the market in the future?

  • Who are the top market players? What are their happenings, current developments, and scenarios?

  • Who are the emerging players? What are their happenings, clinical development, platform technology, phase, and current developments?

  • How is the market predicted to develop in the future?

Key Topics Covered:

1. Executive Summary

2. United States Hepatitis Vaccines Market Size and Forecast (2015 - 2027)

3. Key Marketed Hepatitis Vaccines Market Value in the United States (2015 - 2027)
3.1 Havrix/Twinrix/Engerix-B
3.2 Vaqta
3.3 Recombivax HB
3.4 Heplisav-B

4. Key Drivers and Inhibitors of the United States Hepatitis Vaccines Market
4.1 Market Drivers
4.2 Market Inhibitors

5. United States Hepatitis Vaccines Pricing Trends and Analysis

6. Reimbursement Environment of the United States Hepatitis Vaccines Market

7. Regulatory Framework of the United States Hepatitis Vaccines Market

8. Hepatitis Vaccines Clinical Trials Insight by Phase, Company, and Country

9. Key Companies Profiles (Business Overview, Key Marketed Hepatitis Vaccines, and Recent Development)
9.1 Merck
9.2 GlaxoSmithKline (GSK)
9.3 Dynavax Technologies

10. Emerging Player Profiles (Business Overview, Promising Vaccines in the Clinical Development, and Recent Development)
10.1 Vaccitech
10.2 VBI Vaccines
10.3 GeoVax
10.4 GeneOne Life Science
10.5 Cytuvax

For more information about this report visit https://www.researchandmarkets.com/r/g2po6v

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900